<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711618</url>
  </required_header>
  <id_info>
    <org_study_id>DHF19571</org_study_id>
    <nct_id>NCT02711618</nct_id>
  </id_info>
  <brief_title>Non-Invasive Abdominal Fat Reduction With BMI Above 28</brief_title>
  <official_title>Clinical Study to Evaluate the Performance of the UltraShape Contour I V3 for Non-Invasive Abdominal Fat Reduction Among Patients With BMI Above 28</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, one arm, baseline-controlled clinical study for the evaluation of UltraShape
      contour I V3 for non-invasive fat reduction.

      The study will conduct using the UltraShape contour I V3 using U-Sculpt/VDF transducer on the
      abdomen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, one arm, up to four sites, clinical study showing the
      performance and safety of the UltraShape contour I V3 device non-invasive abdominal fat
      reduction for subjects with body mass index (BMI) above 28.

      Up to 60 healthy subjects will be enrolled. All subjects will undergo an assessment of their
      general health. During the treatment period, subject's fat thickness and circumferences will
      be measured and three successive UltraShape contour I V3 treatments will be performed (two
      weeks interval).

      Subjects will undergo treatment with the UltraShape contour I V3 using the U-Sculpt/VDF
      transducer on the abdomen area.

      Follow-up (FU) visits will be conducted as follows: 4 weeks FU, 8 weeks FU and 12 weeks FU
      post last treatment (Tx.3). Subject's fat thickness and circumference will be measured at
      each visit. Subject's blood test will be taken at baseline (prior to the first treatment, pre
      Tx.1), before the third treatment (pre Tx.3) and at 12 weeks follow-up visit (12wk FU). &quot;No
      Pregnancy&quot; will be verified before first treatment as well. In all following visits (TX2, Tx3
      and FU 1 FU 2 and FU3), lack of pregnancy will be verified by questioning. Additionally,
      subject satisfaction and investigator satisfaction questionnaires will be completed at each
      FU visit. Finally, photography will be performed under visible light conditions of the front,
      right and left view. Optional, 3D photographs will be taken at each visit (at treatment
      visits, prior to treatments).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in abdominal fat thickness compared to baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Abdominal fat thickness reduction post UltraShape contour I V3 treatments at 12 weeks follow-up (12wk FU) versus baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal fat thickness compared to baseline</measure>
    <time_frame>Baseline, 8 weeks and 16 weeks</time_frame>
    <description>Abdominal fat thickness reduction as measured by Ultrasound device post UltraShape contour I V3 treatments at follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal fat thickness compared to baseline</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks, and 16 weeks</time_frame>
    <description>Abdominal fat thickness reduction as measured by caliper post UltraShape contour I V3 treatments at follow-up visits versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal circumference reduction compared to baseline</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks</time_frame>
    <description>Abdominal circumference reduction post UltraShape contour I V3 treatments at all treatment visits and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood panel and fat lipid profile compared to baseline levels</measure>
    <time_frame>Baseline, 4 weeks and 16 weeks</time_frame>
    <description>Blood elements levels (e.g. lipids, Glucose) before the third treatment (at 4 weeks) and at the last follow-up visit (at 16 weeks) versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator satisfaction</measure>
    <time_frame>8 weeks, 12 weeks, and 16 weeks</time_frame>
    <description>Investigator satisfaction: success is defined as when at least 50% of the observations are ranked as at least satisfied by the study investigator at each of the follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>8 weeks, 12 weeks, and 16 weeks</time_frame>
    <description>Subject satisfaction: success is defined as when at least 50% of the subjects are satisfied with treatment results at each of the follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort level during treatment</measure>
    <time_frame>day 0, 2 weeks, and 4 weeks</time_frame>
    <description>Comfort assessment will be performed independently by subjects using a numerical scale. Subjects will assess treatment comfort immediately post each of the three treatments</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>day 0 until 16 weeks</time_frame>
    <description>Description, severity, intervention and outcome of adverse events will be reported on an adverse event form and number of participants will be reported</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Unwanted Fat</condition>
  <arm_group>
    <arm_group_label>UltraShape Contour I V3 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UltraShape Contour I V3</intervention_name>
    <description>Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time</description>
    <arm_group_label>UltraShape Contour I V3 treatment</arm_group_label>
    <other_name>Contour I V3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        subject is eligible to participate in the study if he or she meets all the following
        inclusion criteria:

          1. Signed informed consent to participate in the study.

          2. Female and male subjects,18 and 60 years of age at the time of enrolment

          3. Fitzpatrick Skin Type I to VI.

          4. Abdominal fat thickness of at least 1.5 cm (measured by calibrated caliper).

          5. BMI above 28 (normal to overweight).

          6. If female, not pregnant, lactating and must be either post-menopausal, surgically
             sterilized, or using a medically acceptable form of birth control at least 3 months
             prior to enrollment (i.e. oral contraceptives, contraceptive implant, barrier methods
             with spermicide or abstinence).

          7. Negative urine pregnancy test as tested before the first treatment for women with
             bearing potential (e.g. not menopause). In addition, negative pregnancy following
             pregnancy inquiry for each visit (treatments and follow up), starting from the second
             treatment.

          8. General good health confirmed by medical history and skin examination of the treated
             area.

          9. Willing to follow the treatment and follow-up schedule and post-treatment care
             instructions.

         10. Willingness to refrain from a change in diet/ exercise/medication regimen for the
             entire course of the study.

         11. Willing to have photographs and images taken of the treated areas to be used
             de-identified in evaluations, publications and presentations

        Exclusion Criteria:

        A subject is not eligible for participation in this study if he/she meets any of the
        following exclusion criteria:

          1. History of hypertension, ischemic heart disease, valvular heart disease, congestive
             heart failure, pacemaker/defibrillator, abdominal aortic aneurism

          2. Current hyperlipidemia, hepatitis, liver disease, HIV positive status, blood
             coagulopathy or excessive bleeding, autoimmune or connective tissue disease or
             malignancy

          3. Previous liposuction or body contouring procedures in the treatment areas of the
             abdomen or flanks. History of skin disease in the treatment area, known tendency to
             form keloids or poor wound healing.

          4. Skin lesions in the treatment area other than simple nevi on physical examination
             (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment
             area.

          5. Poor skin quality (i.e., laxity).

          6. Abdominal wall diastasis or hernia on physical examination.

          7. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count
             within the last 3 months.

          8. Childbirth within the last 12 months or breastfeeding women.

          9. Any acute or chronic condition which, in the opinion of the investigator, could
             interfere with the conduct of the study.

         10. Unstable weight within the last 6 months (i.e., Â± 3 percent weight change in the prior
             six months).

         11. Inability to comply with circumference measurement procedure (e.g., inability to hold
             breath for the required duration).

         12. Abdominal fat thickness lower than 2.5 cm after strapping.

         13. Participation in another clinical study within the last 6 months.

         14. Non-invasive body-contouring procedures in the treatment area completed less than
             twelve months prior to study enrollment.

         15. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan H Gold, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aesthetic Plastic Surgery &amp; Cosmetic Medicine Great Neck, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanctuary Plastic Surgery</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>833 Northern Boulevard</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser and Skin Surgery Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arner P. Regional adipocity in man. J Endocrinol. 1997 Nov;155(2):191-2. Review.</citation>
    <PMID>9415044</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

